Physician profile
Ryan Dabbs
NPI 1639307713
$4,294.79
in general payments reported to CMS, 2019-2025
14 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $195 · 2021: $602 · 2022: $1,744 · 2023: $647 · 2024: $146 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $586 · Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $586.43 |
| Food and Beverage | $366.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $2,529.52 | 2019-2025 | Comprehensive, Persona, Tapestry |
| Alpha Orthopedic Systems | $731.17 | 2019-2021 | |
| Smith+Nephew, INC. | $198.04 | 2019-2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Smoky Mountain Surgical LLC | $190.52 | 2023-2025 | |
| Conformis, INC. | $150.00 | 2019 | |
| Medacta USA, INC. | $123.57 | 2021 | |
| Medartis INC. | $118.80 | 2020-2022 | |
| Horizon Therapeutics Plc | $58.52 | 2019-2020 | |
| Stryker Corporation | $54.29 | 2019-2020 | |
| Amgen INC. | $52.93 | 2019 | |
| Ferring Pharmaceuticals INC. | $46.26 | 2019-2020 | |
| Ibsa Pharma INC. | $16.31 | 2023 | Licart, Tirosint |
| Cumberland Pharmaceuticals, INC. | $12.55 | 2019 | |
| Pacira Therapeutics, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Dabbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.